Sato et al 1 describe, in this issue of the Journal of Human Hypertension, a blunted hypotensive response to exogenous L-arginine, the precursor of nitric oxide (NO), in effectively treated hypertensive patients with a remote history of accelerated hypertension as compared with uncomplicated hypertensives otherwise similar for clinical characteristics. The authors legitimately attribute the reduced drop in pressure to defective NO generation, but the reader should be aware of some drawbacks of L-arginine infusion as a test of endothelial function. The experimental procedure is based upon two main assumptions. The first, that exogenous provision of additional substrate for the endothelial nitric oxide synthase (eNOS) enhances NO production. The second that augmented NO production decreases systemic blood pressure by vasorelaxing resistance vessels, so that blood pressure becomes a surrogate measure of systemic vasodilatation. However, the first assumption may be only partially valid to the extent that exogenous L-arginine produces NO through indirect biochemical mechanisms additional to eNOS stimulation, as detailed in recent publications.
Sato et al 1 describe, in this issue of the Journal of Human Hypertension, a blunted hypotensive response to exogenous L-arginine, the precursor of nitric oxide (NO), in effectively treated hypertensive patients with a remote history of accelerated hypertension as compared with uncomplicated hypertensives otherwise similar for clinical characteristics. The authors legitimately attribute the reduced drop in pressure to defective NO generation, but the reader should be aware of some drawbacks of L-arginine infusion as a test of endothelial function. The experimental procedure is based upon two main assumptions. The first, that exogenous provision of additional substrate for the endothelial nitric oxide synthase (eNOS) enhances NO production. The second that augmented NO production decreases systemic blood pressure by vasorelaxing resistance vessels, so that blood pressure becomes a surrogate measure of systemic vasodilatation. However, the first assumption may be only partially valid to the extent that exogenous L-arginine produces NO through indirect biochemical mechanisms additional to eNOS stimulation, as detailed in recent publications. 2 More importantly, L-arginine availability for the reaction with the enzyme does not seem rate limiting, were it not because the intracellular concentration of the amino acid ranges in the millimolar range as opposed to an enzyme's K m for substrate in the micromolar range. 2 In agreement with this objection, local supplementation with Larginine did not normalise the defective vasomotor response to acetylcholine infused into the brachial artery of essential hypertensive patients. 3 The following point in the reasoning, ie, that increased NO generation induces selective peripheral vasodilatation reliably recorded by indirect blood pressure measurement, is challenged by the haemodynamic pattern of unchanged heart rate in spite of a rapidly decreasing pressure. Although the authors disre-garded this unexpected behaviour as a mere drug interference, the same finding was reported under more standardised conditions. 4 Hypotension in the absence of tachycardia and without increments in catecholamines and plasma renin activity, ie, the markers of the reflexogenic sympathetic activation usually expected in response to agents with pure arteriolar relaxing property, 5 implies an interaction, specific or not, with the central pathways of cardiovascular control. Therefore, the action of L-arginine on peripheral vascular resistance may be confounded by activation or deactivation of autonomic reflexes that the authors did not investigate. Finally, it should be taken into account that blood pressure compounds peripheral resistance and cardiac output, and the latter may have undergone unpredictable modifications, thus introducing further complexities.
Having said this, and keeping in mind the above limitations, the lack of response to L-arginine in the hypertensive group with a remote history of accelerated/malignant hypertension was quite striking and interesting in its implications. Furthermore, acute intravenous and chronic oral L-arginine convincingly and consistently improved NO-mediated vascular functions in hypercholesterolaemia, in small-vessel disease, in exercising patients with stable angina pectoris, and at sites of coronary artery stenosis. [6] [7] [8] [9] It is likely, therefore, that the data did reflect a reduced NO bioavailability referred in generic terms to endothelial dysfunction. 11 Such a broad definition encompasses, strictly speaking, all the biological functions subserved by vascular endothelium, a structure intimately involved in fibrinolysis, haemostasis and permeability control (eg, see Vane et al) . 10 However, the present results are pertinent only to NO-mediated vasomotion, and do not allow inferences about other endothelial functions that may follow an unrelated evolution.
11
Uncertainties arise also about the cause-effect profile of a phenomenon that may not necessarily represent the irreversible and sub-clinical consequence of a clinically healed disease, as the authors hypothesise on the basis of their cross-sectional study. Vice versa, defective endothelial vasomotion may have pre-existed and perhaps promoted the development of accelerated/malignant hypertension. Alternatively, one might even argue that the association of past history of accelerated hypertension and unresponsiveness to L-arginine was purely coincidental. Furthermore, a defective response to exogenous Larginine does not necessarily imply an abnormal endogenous NO-mediated tone, a possibility to be addressed by inhibiting NO-generation through the use of antagonists rather than stimulating acutely its generation by agonists. A preserved tonic activity of the endogenous L-arginine-NO system might explain why resting blood pressure did not differ between the two groups. Perhaps endothelial NO release may be more important in modulating shortterm blood pressure changes, a hypothesis consistent with the reports of exaggerated responses to static and dynamic exercise in patients with a distant history of accelerated hypertension. 12 It is not irrelevant to quote, in this context, the amelioration of the pressor response to mental stress in essential hypertensive patients treated with statins, 13 a class of drugs beneficial on NO-mediated vasomotion through still incompletely understood mechanisms.
14 How the abnormal acute blood pressure to L-arginine of this group of normo-cholesterolaemic, endothelial dysfunctional hypertensive patients might have reacted in response to statin treatment is an interesting question to be possibly tested in the future.
The study of Sato et al 1 is worthy of a final, more general comment. In showing such a marked drop in blood pressure during the infusion of L-arginine, one has to deduce that endothelial vasomotor function is preserved in some essential hypertensive patients. Since a normotensive group was not included as a control, it is impossible to classify the entity of hypotension as normal, subnormal or supernormal, though. However, preserved responses to NO releasing compounds have been repeatedly shown in the forearm 12, [15] [16] [17] [18] and coronary 19, 20 vascular bed as well as in isolated resistance-sized arterioles 21, 22 of uncomplicated hypertensive patients compared with normotensive subjects. Therefore, we should probably see, against more dogmatic views, defective vasomotion in response to endothelial agonists as a disorder affecting subsets of the overall hypertensive population, similar to other peculiar manifestations of essential hypertension such as microalbuminuria 23 or insulin resistance. 24 
